Ataluren is a medicine used to treat a rare genetic condition called Duchenne muscular dystrophy (DMD). It is used to improve muscle function in patients with DMD who have a particular type of genetic mutation called a "nonsense" mutation. This mutation causes a premature stop signal in the gene, which prevents the body from making the protein needed to make healthy muscles. Ataluren is designed to bypass this stop signal and allow the body to make the needed protein. Studies have shown that Ataluren can improve muscle function and quality of life in patients with DMD.
Ataluren, sold under the brand name Translarna, is a medication used for the treatment of Duchenne muscular dystrophy (DMD) in ambulatory patients aged 5 years and older who have a nonsense mutation in the dystrophin gene. It is the first medication approved for the treatment of this specific genetic form of DMD.
DMD is a genetic disorder characterized by progressive muscle weakness and loss of muscle mass. It is caused by mutations in the dystrophin gene, which is responsible for the production of a protein called dystrophin. Dystrophin helps to keep muscle cells healthy and strong. Nonsense mutations are a specific type of mutation that prematurely stop the production of dystrophin, resulting in a shortened and non-functional protein.
Ataluren works by enabling the ribosomes (the protein-making machinery in cells) to "read through" nonsense mutations in the dystrophin gene. This allows the ribosomes to continue producing a full-length, although partially functional, dystrophin protein. While not a cure, this can help to slow the progression of muscle weakness and loss in some patients.
Ataluren is an orally administered medication, typically taken three times a day. The most common side effects of ataluren include headache, nausea, vomiting, diarrhea, and fatigue.
It is important to note that ataluren is not a cure for DMD, and it does not work for all patients. It is also important to note that ataluren is not approved for use in the United States by the Food and Drug Administration (FDA). However, it is approved for use in the European Union and other countries.
Here are some additional points to consider about ataluren:
- Ataluren is a relatively new medication, and long-term safety and efficacy data are still limited.
- Ataluren is a very expensive medication.
- Clinical trials of ataluren have shown mixed results, with some studies showing modest benefits and others showing no significant benefit.
If you are considering ataluren for the treatment of DMD, it is important to discuss the risks and benefits of this medication with your doctor.